NeuroSense Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Alon Ben-Noon, NeuroSense Therapeutics operates with 11–50 employees. The company has raised $24.2 million across 7 funding rounds from 2 investors. In November 2025, NeuroSense received FDA clearance to initiate a pivotal Phase 3 trial for its lead drug candidate, PrimeC, in ALS.

Business overview

NeuroSense Therapeutics is a drug development company focused on creating treatments for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its core product, PrimeC, is a unique formulation combining two FDA-approved compounds. The company is actively engaged in clinical trials for PrimeC in ALS patients in Israel and the United States, serving the pharmaceutical and life sciences markets within the Health Tech & Life Sciences sector.

Strategic signal

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS. This regulatory milestone is a significant validation of the drug's potential and marks a critical step towards commercialization, indicating a strong forward trajectory for the company in the neurodegenerative disease market.

Company Intelligence Q&A

What was a significant regulatory achievement for NeuroSense Therapeutics in late 2025?

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for its lead drug candidate, PrimeC, in ALS.

What recent funding activity did NeuroSense Therapeutics announce?

In September 2025, NeuroSense Therapeutics announced a $500,000 private placement at a premium to its market price.

What intellectual property milestone did NeuroSense Therapeutics achieve in September 2024?

In September 2024, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for ALS and Alzheimer's.

What strategic move did NeuroSense Therapeutics plan for its ALS treatment in Canada in October 2024?

In October 2024, NeuroSense Therapeutics announced plans to file for early commercialization of its ALS treatment in Canada.

What was the outcome of NeuroSense Therapeutics' at-the-market equity offering program in October 2023?

In October 2023, NeuroSense Therapeutics ended its at-the-market equity offering program, stating the company is fully funded beyond its clinical Phase 2b ALS results.